Clinical Trials Browser

Phase 2 × Inflammation × 90 days × Clear all

Inflammation, Lung Neoplasms, Motor Activity, Smoking Cessation

NCT06068543 2026-03-06

ReFOCUS2

Phase 2 Recruiting

118 enrolled

Frailty, Inflammation

NCT05522387 2026-02-27

An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease

Phase 2 Terminated

11 enrolled

CNS

Alzheimer Disease, Mental Disorders, Brain Diseases, Central Nervous System Diseases, Dementia, Inflammation, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Tauopathies

Clinical Trials

SMILE

ReFOCUS2

An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease